Local Failure after Prostate SBRT Predominantly Occurs in the PI-RADS 4 or 5 Dominant Intraprostatic Lesion

被引:16
作者
Gorovets, Daniel [1 ]
Wibmer, Andreas G. [2 ]
Moore, Assaf [1 ,3 ]
Lobaugh, Stephanie [4 ]
Zhang, Zhigang [4 ]
Kollmeier, Marisa [1 ]
McBride, Sean [1 ]
Zelefsky, Michael J. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10065 USA
[3] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[4] Mem Sloan Kettering Canc, Dept Epidemiol & Biostat, New York, NY 10065 USA
基金
美国国家卫生研究院;
关键词
Prostate cancer; SBRT; PI-RADS; Biopsy; BODY RADIATION-THERAPY; POSTTREATMENT BIOPSY; CANCER RADIOTHERAPY; PRIMARY TUMOR; INTERMEDIATE; OUTCOMES; RECURRENCE; TRIAL; SITE; MRI;
D O I
10.1016/j.euo.2022.02.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background:A positive post-treatment prostate biopsy following definitive radiotherapy carries significant prognostic implications. Objective:To determine whether local recurrences after prostate stereotactic body radiation therapy (SBRT) are associated with the presence of and occur more commonly within the region of a PI-RADS 4 or 5 dominant intra-prostatic lesion (DIL) identified on pre-treatment multi-parametric magnetic resonance imaging (MRI). Design, Setting, and Participants:247 patients with localized prostate cancer treated with SBRT at our institution from 2009-2018 underwent post-treatment biopsies (median time to biopsy: 2.2 years) to evaluate local control. Interventions:Prostate SBRT (median 40 Gy in 5 fractions). Outcome Measurements and Statistical Analysis:MRIs were read by a single diagnostic radiologist blinded to other patient characteristics and treatment outcomes. The DIL presence, size, location, and extent were then analyzed to determine associations with the post-treatment biopsy outcomes. Results and Limitations:Among patients who underwent post-treatment biopsies, 39/247 (15.8%) were positive for Gleason-gradable prostate adenocarcinoma, of which 35/39 (90%) had a DIL initially present and 29/39 (74.4%) had a positive biopsy within the DIL. Factors independently associated with post-treatment biopsy outcomes included the presence of a DIL (OR 6.95; p = 0.001), radiographic T3 disease (OR 5.23, p < 0.001), SBRT dose >40 Gy (OR 0.26, p = 0.003), and use of androgen deprivation therapy (ADT; OR 0.28, p = 0.027). Among patients with a DIL (N = 149), the only factors associated with post-treatment biopsy outcomes included >50% percent cores positive (OR 2.4, p = 0.037), radiographic T3 disease (OR 4.04, p = 0.001), SBRT dose >40 Gy (OR 0.22, p < 0.001), and use of ADT (OR 0.21, p = 0.014). Conclusions:Our results suggest that men with PI-RADS 4 or 5 DILs have a higher risk of local recurrence after prostate SBRT and that most recurrences are located within the DIL. Patient Summary:We found the presence of a dominant tumor on pre-treatment MRI was strongly associated with residual cancer within the prostate after SBRT and that most recurrences were within the dominant tumor. & COPY; 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:275 / 281
页数:7
相关论文
共 31 条
[1]   Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial [J].
Aluwini, Shafak ;
Pos, Floris ;
Schimmel, Erik ;
van Lin, Emile ;
Krol, Stijn ;
van der Toorn, Peter Paul ;
de Jager, Hanja ;
Dirkx, Maarten ;
Alemayehu, Wendimagegn Ghidey ;
Heijmen, Ben ;
Incrocci, Luca .
LANCET ONCOLOGY, 2015, 16 (03) :274-283
[2]   Does Local Recurrence of Prostate Cancer After Radiation Therapy Occur at the Site of Primary Tumor? Results of a Longitudinal MRI and MRSI Study [J].
Arrayeh, Elnasif ;
Westphalen, Antonio C. ;
Kurhanewicz, John ;
Roach, Mack, III ;
Jung, Adam J. ;
Carroll, Peter R. ;
Coakley, Fergus V. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (05) :E787-E793
[3]   Why prostate tumour delineation based on apparent diffusion coefficient is challenging: An exploration of the tissue microanatomy [J].
Borren, Alie ;
Moman, Maaike R. ;
Groenendaal, Greetje ;
Kruger, Arto E. Boeken ;
van Diest, Paul J. ;
van der Groep, Petra ;
van der Heide, Uulke A. ;
van Vulpen, Marco ;
Philippens, Marielle E. P. .
ACTA ONCOLOGICA, 2013, 52 (08) :1629-1636
[4]   Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial [J].
Brand, Douglas H. ;
Tree, Alison C. ;
Ostler, Peter ;
van der Voet, Hans ;
Loblaw, Andrew ;
Chu, William ;
Ford, Daniel ;
Tolan, Shaun ;
Jain, Suneil ;
Martin, Alexander ;
Staffurth, John ;
Camilleri, Philip ;
Kancherla, Kiran ;
Frew, John ;
Chan, Andrew ;
Dayes, Ian S. ;
Henderson, Daniel ;
Brown, Stephanie ;
Cruickshank, Clare ;
Burnett, Stephanie ;
Duffton, Aileen ;
Griffin, Clare ;
Hinder, Victoria ;
Morrison, Kirsty ;
Naismith, Olivia ;
Hall, Emma ;
van As, Nicholas .
LANCET ONCOLOGY, 2019, 20 (11) :1531-1543
[5]   Twenty-Four-Month Postradiation Prostate Biopsies Are Strongly Predictive of 7-Year Disease-free Survival [J].
Crook, Juanita M. ;
Malone, Shawn ;
Perry, Gad ;
Eapen, Libni ;
Owen, Julie ;
Robertson, Susan ;
Ludgate, Charles ;
Fung, Sharon ;
Lockwood, Gina ;
Math, M. .
CANCER, 2009, 115 (03) :673-679
[6]   Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer [J].
Draulans, Cedric ;
van der Heide, Uulke A. ;
Haustermans, Karin ;
Pos, Floris J. ;
van Zyp, Jochem van der Voort ;
De Boer, Hans ;
Groen, Veerle H. ;
Monninkhof, Evelyn M. ;
Smeenk, Robert J. ;
Kunze-Busch, Martina ;
De Roover, Robin ;
Depuydt, Tom ;
Isebaert, Sofie ;
Kerkmeijer, Linda G. W. .
RADIOTHERAPY AND ONCOLOGY, 2020, 147 :92-98
[7]   Multi-Institutional Phase 2 Trial of High-Dose Stereotactic Body Radiation Therapy with Temporary Hydrogel Spacer for Low- and Intermediate-Risk Prostate Cancer [J].
Folkert, M. R. ;
Zelefsky, M. J. ;
Hannan, R. ;
Desai, N. B. ;
Lotan, Y. ;
Laine, A. M. ;
Kim, D. W. N. ;
Hardee, S. ;
Hornberger, B. ;
Kollmeier, M. A. ;
McBride, S. ;
Xie, X. J. ;
Roehrborn, C. ;
Timmerman, R. D. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (05) :1319-1320
[8]   Target motion mitigation promotes high -precision treatment planning and delivery of extreme hypofractionated prostate cancer radiotherapy: Results from a phase II study [J].
Greco, Carlo ;
Pares, Oriol ;
Pimentel, Nuno ;
Louro, Vasco ;
Morales, Javier ;
Nunes, Beatriz ;
Vasconcelos, Ana Luisa ;
Antunes, Ines ;
Kociolek, Justyna ;
Stroom, Joep ;
Viera, Sandra ;
Mateus, Dalila ;
Cardoso, Maria Joao ;
Soares, Ana ;
Marques, Joao ;
Freitas, Elda ;
Coelho, Graca ;
Fuks, Zvi .
RADIOTHERAPY AND ONCOLOGY, 2020, 146 :21-28
[9]   Simultaneous MRI diffusion and perfusion imaging for tumor delineation in prostate cancer patients [J].
Groenendaal, Greetje ;
van den Berg, Cornelis A. T. ;
Korporaal, Jan G. ;
Philippens, Marielle E. P. ;
Luijten, Peter R. ;
van Vulpen, Marco ;
van der Heide, Uulke A. .
RADIOTHERAPY AND ONCOLOGY, 2010, 95 (02) :185-190
[10]   Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial [J].
Hannan, Raquibul ;
Tumati, Vasu ;
Xie, Xian-Jin ;
Cho, L. Chinsoo ;
Kavanagh, Brian D. ;
Brindle, Jeffrey ;
Raben, David ;
Nanda, Akash ;
Cooley, Susan ;
Kim, D. W. Nathan ;
Pistenmaa, David ;
Lotan, Yair ;
Timmerman, Robert .
EUROPEAN JOURNAL OF CANCER, 2016, 59 :142-151